Applied dna second fiscal quarter 2021 financial results feature 384% year-over-year growth in revenues

Stony brook, n.y.--(business wire)---- $apdn #covid19--applied dna sciences, inc. (nasdaq: apdn) (the “company”), a leader in polymerase chain reaction (pcr)-based dna manufacturing, today announced consolidated financial results for the three and six months ended march 31, 2021. “we are pleased to deliver a strong fiscal second quarter with year-over-year revenue growth of 384%, capping an impressive first half of the fiscal year distinguished by demand for our covid-19 diagnostics and surveillance testing offer
APDN Ratings Summary
APDN Quant Ranking